Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis
Recruiting
Dompé US
Phase 4
2020-09-09
This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL)
cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis
Recruiting
Dompé Farmaceutici S.p.A
Phase 4
2020-09-09
This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL)
cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
Study to Evaluate Safety and Efficacy of Oxervate® Ophthalmic Solution vs Vehicle in Severe Sjogren's Dry Eye Disease
Not yet recruiting
Dompé Farmaceutici S.p.A
Phase 3
2021-11-30
The study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic
solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients
with severe Sjogren's dry eye disease.
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) 20 mcg/mL vs Vehicle, in Patients With Sjogren's Dry Eye
Not yet recruiting
Dompé Farmaceutici S.p.A
Phase 3
2021-12-01
The study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic
solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients
with severe Sjogren's dry eye disease (DED) who are under chronic treatment with topical
Cyclosporine A (CsA).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
